Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

10.23 +0.02 (+0.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,398,082
Open 10.36
Bid (Size) 9.680 (1)
Ask (Size) 10.70 (10)
Prev. Close 10.21
Today's Range 10.10 - 10.77
52wk Range 6.850 - 54.74
Shares Outstanding 122,816,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NeoGenomics Announces Chief Executive Officer Appointment
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board 
From NeoGenomics, Inc.
Via AccessWire

Performance

YTD
-70.98%
-70.98%
1 Month
+20.21%
+20.21%
3 Month
+25.06%
+25.06%
6 Month
-52.90%
-52.90%
1 Year
-77.53%
-77.53%

More News

Read More
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
From NeoGenomics, Inc.
Via AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Analyst Ratings for NeoGenomics
Via Benzinga
NeoGenomics: Q1 Earnings Insights
Via Benzinga
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
From NeoGenomics, Inc.
Via AccessWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Analyst Ratings for NeoGenomics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
From NeoGenomics, Inc.
Via AccessWire
Earnings Scheduled For May 13, 2022
Via Benzinga
NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
From NeoGenomics, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
NeoGenomics Reports Revenue of $117 Million in the First Quarter
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.